Abstract
Eph receptors are a unique family of receptor tyrosine kinases (RTK) that play critical roles in embryonic patterning, neuronal targeting, and vascular development during embryogenesis. In adults, Eph RTKs and their ligands, the ephrins, are frequently overexpressed in a variety of cancers and tumor cell lines, including breast, prostate, non-small cell lung and colon cancers, melanomas, and neuroblastomas. Unlike traditional oncogenes that often function only in tumor cells, recent data show that Eph receptors mediate cell-cell interaction both in tumor cells and in tumor microenvironment, namely the tumor stroma and tumor vasculature. As such, Eph RTKs represent attractive potential targets for drug design, as targeting these molecules could attack several aspects of tumor progression simultaneously. This review will focus on recent advances in dissecting the role of Eph RTKs in tumor cells, tumor angiogenesis, and possible contribution to trafficking of inflammatory cells in cancer.
Keywords: eph receptors, receptor tyrosine kinases, ligands, signaling, cancer cells, tumor cells, tumor microenvironment, tumor anglogenesis
Current Pharmaceutical Design
Title: Eph Receptor Tyrosine Kinases in Tumor and Tumor Microenvironment
Volume: 10 Issue: 27
Author(s): Dana Brantley-Sieders, Sonja Schmidt, Monica Parker and Jin Chen
Affiliation:
Keywords: eph receptors, receptor tyrosine kinases, ligands, signaling, cancer cells, tumor cells, tumor microenvironment, tumor anglogenesis
Abstract: Eph receptors are a unique family of receptor tyrosine kinases (RTK) that play critical roles in embryonic patterning, neuronal targeting, and vascular development during embryogenesis. In adults, Eph RTKs and their ligands, the ephrins, are frequently overexpressed in a variety of cancers and tumor cell lines, including breast, prostate, non-small cell lung and colon cancers, melanomas, and neuroblastomas. Unlike traditional oncogenes that often function only in tumor cells, recent data show that Eph receptors mediate cell-cell interaction both in tumor cells and in tumor microenvironment, namely the tumor stroma and tumor vasculature. As such, Eph RTKs represent attractive potential targets for drug design, as targeting these molecules could attack several aspects of tumor progression simultaneously. This review will focus on recent advances in dissecting the role of Eph RTKs in tumor cells, tumor angiogenesis, and possible contribution to trafficking of inflammatory cells in cancer.
Export Options
About this article
Cite this article as:
Brantley-Sieders Dana, Schmidt Sonja, Parker Monica and Chen Jin, Eph Receptor Tyrosine Kinases in Tumor and Tumor Microenvironment, Current Pharmaceutical Design 2004; 10 (27) . https://dx.doi.org/10.2174/1381612043383160
DOI https://dx.doi.org/10.2174/1381612043383160 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hemoglobin Neurotoxicity is Attenuated by Inhibitors of the Protein Kinase CK2 Independent of Heme Oxygenase Activity
Current Neurovascular Research Oxazolidinones as Chiral Auxiliaries in the Asymmetric 1,4-Conjugate Addition Reaction Applied to the Total Synthesis of Natural Products: A Supplemental Mini-Review
Current Organic Synthesis High-Risk Neuroblastoma: Poor Outcomes Despite Aggressive Multimodal Therapy
Current Cancer Therapy Reviews Molecular Targeting of Cell Death Signal Transduction Pathways in Cancer
Current Signal Transduction Therapy The Endocannabinoid System in Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Characterizing the Relationship Between the Chemical Structures of Drugs and their Activities on Primary Cultures of Pediatric Solid Tumors
Current Medicinal Chemistry Membrane Rafts in the Respiratory System
Current Respiratory Medicine Reviews Targeting the Endocannabinod System to Limit Myocardial and Cerebral Ischemic and Reperfusion Injury
Current Pharmaceutical Biotechnology Cellular and Biochemical Alterations Caused by Artificial Depletion of Glutathione
Current Enzyme Inhibition Potential Interactions between miRNAs and Hypoxia: A New Layer in Cancer Hypoxia
Anti-Cancer Agents in Medicinal Chemistry Caspase-Independent Pathways of Programmed Cell Death: The Unraveling of New Targets of Cancer Therapy?
Current Cancer Drug Targets Fluorescent GPCR Ligands as New Tools in Pharmacology-Update, Years 2008- Early 2014
Current Medicinal Chemistry Circadian Timekeeping in Anticancer Therapeutics: An Emerging Vista of Chronopharmacology Research
Current Drug Metabolism Epigenetic Aberrations and Targeted Epigenetic Therapy of Esophageal Cancer
Current Cancer Drug Targets Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Emerging Roles of MicroRNA-22 in Human Disease and Normal Physiology
Current Molecular Medicine Indolinones as Promising Scaffold as Kinase Inhibitors: A Review
Mini-Reviews in Medicinal Chemistry Rifampicin Induced Aggregation of Ovalbumin: Malicious Behaviour of Antibiotics
Protein & Peptide Letters The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy
Current Pharmaceutical Design Nitric Oxide Control of Proliferation in Nerve Cells and in Tumor Cells of Nervous Origin
Current Pharmaceutical Design